The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASC
Open accessAbstract
Severe acute respiratory syndrome Coronavirus (SARS‐CoV) is capable of inducing a storm of proinflammatory cytokines. In this study, we show that the SARS‐CoV open reading frame 3a (ORF3a) accessory protein activates the NLRP3 inflammasome by promoting TNF receptor‐associated factor 3 (TRAF3)–mediated ubiquitination of apoptosis‐associated speck‐like protein containing a caspase recruitment domain (ASC). SARS‐CoV and its ORF3a protein were found to be potent activators of pro–IL‐1β gene transcription and protein maturation, the 2 signals required for activation of the NLRP3 inflammasome. ORF3a induced pro–IL‐1β transcription through activation of NF‐κB, which was mediated by TRAF3‐dependent ubiquitination and processing of p105. ORF3a‐induced elevation of IL‐1β secretion was independent of its ion channel activity or absent in melanoma 2 but required NLRP3, ASC, and TRAF3. ORF3a interacted with TRAF3 and ASC, colocalized with them in discrete punctate structures in the cytoplasm, and facilitated ASC speck formation. TRAF3‐dependent K63‐linked ubiquitination of ASC was more pronounced in SARS‐CoV–infected cells or when ORF3a was expressed. Taken together, our findings reveal a new mechanism by which SARS‐CoV ORF3a protein activates NF‐κB and the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of p105 and ASC.—Siu, K.‐L., Yuen, K.‐S., Castano‐Rodriguez, C., Ye, Z.‐W., Yeung, M.‐L., Fung, S.‐Y., Yuan, S., Chan, C.‐P., Yuen, K.‐Y., Enjuanes, L., Jin, D.‐Y. Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASC. FASEB J. 33, 8865–8877 (2019). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Inflammasomes: mechanism of assembly, regulation and signalling
Broz, P., & Dixit, V. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.58 · Cited by 3,500
Crosstalk in NF-κB Signaling Pathways
Oeckinghaus, A., Hayden, M. S., & Ghosh, S. (2011) · Nature Immunology · doi:10.1038/ni.2065 · Cited by 1,942
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., & Mosialos, G. (2003) · Nature · doi:10.1038/nature01803 · Cited by 961
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Self-citationInfluenza virus activates inflammasomes via its intracellular M2 ion channel
Ichinohe, T., Pang, I. K., & Iwasaki, A. (2010) · Nature Immunology · doi:10.1038/ni.1861 · Cited by 631
Hiscott, J., Marois, J., Garoufalis, J., D'Addario, M., Roulston, A., Kwan, I., Pepin, N., Lacoste, J., Nguyen, H., & Bensi, G. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6231 · Cited by 585
Nieto-Torres, J. L., DeDiego, M. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Castaño-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella, V. M., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004077 · Cited by 559
Self-citation
Cited by
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.937486 · Cited by 703
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Heneka, M. T., Golenbock, D., Latz, E., Morgan, D., & Brown, R. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00640-3 · Cited by 555
Structural biology of SARS-CoV-2 and implications for therapeutic development
Yang, H., & Rao, Z. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00630-8 · Cited by 548
Yoshimoto, F. K. (2020) · The Protein Journal · doi:10.1007/s10930-020-09901-4 · Cited by 543
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Targeting the NLRP3 Inflammasome in Severe COVID-19
Freeman, T. L., & Swartz, T. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01518 · Cited by 405
Detection of Viral Infections by Innate Immunity
Carty, M., Guy, C., & Bowie, A. G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114316 · Cited by 395
Fung, S.-Y., Yuen, K.-S., Ye, Z.-W., Chan, C.-P., & Jin, D.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1736644 · Cited by 381
Self-citationMiao, G., Zhao, H., Li, Y., Ji, M., Chen, Y., Shi, Y., Bi, Y., Wang, P., & Zhang, H. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.12.010 · Cited by 354
“SARS-CoV ORF3a has been shown to interact with TRAF3 (Siu et al., 2019).”
BackgroundInfluentialStructural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 348
The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?
Darif, D., Hammi, I., Kihel, A., El Idrissi Saik, I., Guessous, F., & Akarid, K. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104799 · Cited by 326
Inflammasome activation at the crux of severe COVID-19
Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00588-x · Cited by 325
Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs
Kern, D. M., Sorum, B., Mali, S. S., Hoel, C. M., Sridharan, S., Remis, J. P., Toso, D. B., Kotecha, A., Bautista, D. M., & Brohawn, S. G. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00619-0 · Cited by 318
SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns
Redondo, N., Zaldívar-López, S., Garrido, J. J., & Montoya, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708264 · Cited by 299
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Moore, S. C., Penrice-Randal, R., Alruwaili, M., Dong, X., Pullan, S. T., Carter, D. P., Bewley, K., Zhao, Q., Sun, Y., Hartley, C., et al. (2020) · doi:10.1101/2020.03.05.20032011 · Cited by 121
Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections
Stubbs, B. J., Koutnik, A. P., Goldberg, E. L., Upadhyay, V., Turnbaugh, P. J., Verdin, E., & Newman, J. C. (2020) · Med · doi:10.1016/j.medj.2020.06.008 · Cited by 71
Pappritz, K., Lin, J., El-Shafeey, M., Fechner, H., Kühl, U., Alogna, A., Spillmann, F., Elsanhoury, A., Schulz, R., Tschöpe, C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13845 · Cited by 74
NAD+ in COVID-19 and viral infections
Zheng, M., Schultz, M. B., & Sinclair, D. A. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.02.001 · Cited by 62
NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity
Amin, S., Aktar, S., Rahman, M. M., & Chowdhury, M. M. H. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2021.104913 · Cited by 51
Ahmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
Metadata
- Authors
- Siu, K., Yuen, K., Castano‐Rodriguez, C., Ye, Z., Yeung, M., Fung, S., Yuan, S., Chan, C., Yuen, K., Enjuanes, L., & Jin, D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2019-04-29
- Volume
- 33
- Issue
- 8
- Pages
- 8865-8877
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2943109925
- Cited by
- 502
- References
- 66
- FWCI
- 27.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.